Nanotechnology applications in enhancing drug solubility: Formulation strategies and pharmaceutical outcomes
Year: 2024
Type: article
Abstract: Poor aqueous solubility represents a major barrier to oral drug delivery, affecting approximately 40% of marketed drugs and up to 90% of compounds in development pipelines. Nanotechnology offers powerful solutions through multiple mechanisms: increased surface area from size reduction, amorphous state stabilization, and enhanced wetting characteristics. This review examines established nano formulation strategies for solubility enhancement, focusing on clinically validated approaches. Nanosuspensions prepared by wet milling or high-pressure homogenization achieve particle sizes of 100-500 nm, providing 100-500-fold solubility improvements for poorly soluble compounds [1, 2]. Polymeric nanoparticles offer additional benefits of controlled release and targeting capability [3]. Lipid-based nanocarriers including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) enhance solubility while improving lymphatic absorption [4]. Several FDA-approved products demonstrate commercial viability: Emend® (aprepitant), Rapamune® (sirolimus), and Tricor® (fenofibrate) all employ nanocrystal technology [5, 6]. We present quantitative data on enhancement factors achievable with different approaches, ranging from 150-fold for micritization to over 500-fold for optimized nanosuspensions [7]. Critical formulation parameters include particle size distribution, stabilizer selection, and solid-state properties that determine long-term stability [8]. The review provides practical guidance for selecting nano formulation strategies based on drug properties and therapeutic requirements [9, 10].
Authors: Piotr Kowalski, Anna Nowak, Tomasz Wiśniewski, Katarzyna Zielińska
Institution: Jagiellonian University
Language: English
Subfield: Pharmaceutical Science
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W7152553948
